Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
Investing.com - Actinium Pharmaceuticals reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Actinium Pharmaceuticals announced earnings per share of $-0.380 on revenue of $45.00K. Analysts polled by Investing.com EPS of $-0.345 on revenue of $580K.
Actinium Pharmaceuticals 's are up 98.5% and is trading at $11.930 , still down 21.10% from its 52 week high of $15.12 set on Thursday, November 3, 2022.
Actinium Pharmaceuticals follows other major Healthcare sector earnings this month
Actinium Pharmaceuticals's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar